Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 1b clinical study titled ‘A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)’. The study aims to determine the maximum tolerated dose and safety profile of AMG 193, a MTA-cooperative PRMT5 inhibitor, in combination with other therapies for patients with MTAP-deleted thoracic tumors.
The study tests AMG 193, administered orally, both alone and in combination with other drugs like carboplatin, paclitaxel, pembrolizumab, pemetrexed, and sotorasib. These interventions target advanced thoracic tumors, including non-small cell lung cancer (NSCLC) with specific mutations.
This interventional study is non-randomized with a parallel intervention model and no masking, focusing primarily on treatment. It seeks to evaluate the safety and efficacy of the drug combinations.
The study began on September 17, 2024, with its latest update on July 30, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
The study’s progress could influence Amgen’s stock performance, as positive results may enhance investor confidence and market position, especially in the competitive oncology sector. The study’s focus on a specific genetic deletion in tumors might give Amgen a unique edge over competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.